1. Impact of fixed‐dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52‐week randomized, double‐blind, PSO‐LONG trial. (28th March 2022) Authors: Guenther, L.; Takhar, A.; Megna, M.; Sebastian, M.; Nyholm, N.; Thoning, H.; Levin, L.‐Å. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 7(2022) Page Start: 1054 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Quality of life and patient‐perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed‐dose combination Cal/BD foam: A post‐hoc analysis of PSO‐LONG. (21st October 2021) Authors: Jalili, A.; Calzavara‐Pinton, P.; Kircik, L.; Lons‐Danic, D.; Pink, A.; Tyring, S.; de la Cueva, P.; Gooderham, M.; Segaert, S.; Nyholm, N.; Thoning, H.; Petersen, B.; Thaçi, D. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 1(2022) Page Start: 60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗